Using cell-derived particles to deliver therapeutic molecules
Leveraging cell-derived bioparticles for macromolecular delivery
['FUNDING_OTHER'] · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · NIH-10921628
This study is exploring new ways to help deliver important treatments like proteins and RNAs into cells, which could lead to better and safer therapies for different diseases by improving how we produce tiny particles that carry these treatments.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WHITEHEAD INSTITUTE FOR BIOMEDICAL RES (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-10921628 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative methods to deliver macromolecules, such as proteins and RNAs, into cells to treat diseases. It aims to enhance the production of cell-derived bioparticles, which are promising vehicles for delivering these therapeutic agents. By manipulating specific genes in the cells that produce these bioparticles, the researchers hope to improve the efficiency of their production. This approach could lead to safer and more effective treatments for various conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that could benefit from advanced macromolecular therapies, such as genetic disorders or cancers.
Not a fit: Patients who do not have conditions that require macromolecular therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the delivery of therapeutic macromolecules, leading to better treatment outcomes for patients with various diseases.
How similar studies have performed: Previous research has shown promise in using cell-derived bioparticles for drug delivery, indicating that this approach has potential for success.
Where this research is happening
CAMBRIDGE, UNITED STATES
- WHITEHEAD INSTITUTE FOR BIOMEDICAL RES — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAGURAM, ADITYA — WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
- Study coordinator: RAGURAM, ADITYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.